Ing. Ronald Bronsaer, born in 1973 is the CEO of CellMade. He holds a degree as biochemical engineer from Hogeschool Limburg (Maastricht) combined with additional training in cellular and molecular biology (US, UK and Germany). Ronald has broad experience in primary cell isolations and cellular characterization. In 2000, he joined the company Cambrex (Verviers, Belgium) as Technical Service Specialist. In 2001, he moved towards the position of European Product Manager for molecular biology and was relocated to the Cambrex France entity (Paris). In 2004 he became Director of Business Development and led the acquisition of Genolife, a small biotech company in France, specialized in rapid microbial testing. In early 2007, Ronald left Cambrex to establish CellMade.
Dr. Jos Paquaij obtained his PhD at the Free University Amsterdam in pharmaco-chemistry and was a post-doc at Université Catholique de Louvain and Maastricht University with major experience in cellular biology, cardiovascular research and in vivo and ex vivo animal testing. He has been teaching chemistry and biology for 5 years at vocational level and developed educative materials for these subjects within the Dutch national consortium for vocational education. He joined CellMade in September 2010.Myriam Douach, Scientific Project Manager
Myriam Douach holds a Master of Science in Cell Biology from the University of Strasbourg. She is responsible for CellMade’s primary cell production protocols and for developing and investigating inflammatory co-culture cell models. She is also in charge of the development and maintenance of CellMade’s tissue acquisition network. Before joining the company, Myriam worked as a research assistant in cell biology at the “Etablissement Français du Sang”, Strasbourg where she studied immunology. Previous to that, she focused on research into Polyarthritis Rheumatoid and Lyme borreliosis infection at the University Hospital of Strasbourg.Magalie Bordier, Scientific Project Manager
Magalie Bordier, is responsible for establishing protocols in primary cell isolation/culture/characterization, developing 3D inflammatory co-cultures and implementation of client projects. She holds a Master of Science in cell technologies from the University of Poitiers (France) and worked at Solvay Pharma (Dijon, France) for several years, focusing on investigation of nuclear receptors associated with metabolic syndrome, biomarkers identification and management, and implementation of Solvay’s NRA platform applied to drug screening.
There is a growing need for effective companion tests for anti-inflammatory drugs, as patients and FDA concerns grow regarding the costs and unwanted side effects of the TNF-alpha antagonists. This is one area where Cellmade’s technology could be used to identify people who would benefit from such treatments, in addition to giving early warning signs of toxicity before clinical symptoms develop.
In the drug discovery setting, Cellmade’s focus on primary human cells as an in vitro screening tool will prove valuable for identifying candidate drugs that show credible signs of efficacy in the human setting. It will help to de-risk clinical development stages and enable better selection decisions.